Analysts Set CME Group Inc. (NASDAQ:CME) Price Target at $289.75

Shares of CME Group Inc. (NASDAQ:CME) have earned an average rating of “Hold” from the eighteen analysts that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $289.75.

Several equities analysts have weighed in on the company. Piper Sandler cut their price target on CME Group from $329.00 to $295.00 and set an “overweight” rating for the company in a report on Wednesday, July 15th. Rothschild & Co Redburn raised shares of CME Group from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $316.00 to $323.00 in a research note on Thursday, June 11th. Raymond James Financial restated an “outperform” rating and issued a $320.00 target price on shares of CME Group in a report on Thursday, July 2nd. Weiss Ratings cut shares of CME Group from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Finally, The Goldman Sachs Group lowered their price target on shares of CME Group from $267.00 to $245.00 and set a “sell” rating for the company in a report on Tuesday, June 30th.

Key Stories Impacting CME Group

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: New Treasury clearing platform could expand revenue opportunities. CME Group plans to launch CME Securities Clearing on December 7, ahead of an SEC mandate requiring central clearing for certain U.S. Treasury transactions. The service is intended to provide additional clearing capacity, customer choice and capital efficiency, potentially allowing CME to capture new clearing volumes and strengthen its position in the Treasury market. CME Group to Launch CME Securities Clearing
• Positive Sentiment: Shareholder payout remains a support. CME’s approximately $467 million dividend payment, scheduled for September 25, reinforces the company’s strong cash-generation profile and may appeal to income-focused investors. CME Group’s $467 Million Dividend
• Neutral Sentiment: Planned management transition appears orderly. CME named insider Jack Tobin as CFO, succeeding Lynne Fitzpatrick, who is expected to become CEO in March 2027. Internal promotions can reduce succession risk, although investors may monitor execution during the transition. CME Group names Jack Tobin as CFO
• Neutral Sentiment: Market volatility could support trading activity. Conflicting Federal Reserve and Treasury policy signals may increase interest-rate and bond-market volatility, which can lift demand for CME’s hedging products, but also add uncertainty around the economic outlook. Fed and Treasury at Odds
• Negative Sentiment: Regulatory litigation remains an overhang. An amicus brief urged dismissal of CME’s lawsuit against the CFTC concerning Hyperliquid, highlighting continued uncertainty around the exchange’s regulatory disputes and digital-asset ambitions. Hyperliquid Policy Center Files Amicus Brief

CME Group Trading Down 0.2%

CME Group stock opened at $274.07 on Friday. CME Group has a 12 month low of $218.31 and a 12 month high of $329.16. The company has a market capitalization of $98.55 billion, a price-to-earnings ratio of 23.25, a price-to-earnings-growth ratio of 3.25 and a beta of 0.24. The business’s fifty day simple moving average is $262.78 and its two-hundred day simple moving average is $277.43. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.13.

CME Group (NASDAQ:CME) last released its quarterly earnings data on Wednesday, July 22nd. The financial services provider reported $2.99 earnings per share for the quarter, beating the consensus estimate of $2.91 by $0.08. CME Group had a net margin of 63.30% and a return on equity of 15.60%. The firm had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.68 billion. During the same period in the previous year, the company earned $2.96 earnings per share. The firm’s quarterly revenue was up .8% on a year-over-year basis. As a group, equities analysts predict that CME Group will post 12.27 earnings per share for the current fiscal year.

CME Group Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Wednesday, September 9th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $5.20 dividend on an annualized basis and a yield of 1.9%. CME Group’s payout ratio is 44.11%.

Insiders Place Their Bets

In related news, Director William Shepard bought 325 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were acquired at an average price of $230.57 per share, with a total value of $74,935.25. Following the transaction, the director owned 260,442 shares of the company’s stock, valued at $60,050,111.94. The trade was a 0.12% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.30% of the stock is currently owned by company insiders.

Institutional Trading of CME Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CME. Empowered Funds LLC grew its stake in shares of CME Group by 11.5% in the 1st quarter. Empowered Funds LLC now owns 10,027 shares of the financial services provider’s stock worth $2,660,000 after acquiring an additional 1,037 shares in the last quarter. Marshall Wace LLP boosted its holdings in CME Group by 103.1% in the 2nd quarter. Marshall Wace LLP now owns 3,692 shares of the financial services provider’s stock valued at $1,018,000 after purchasing an additional 121,707 shares during the period. Federated Hermes Inc. boosted its position in shares of CME Group by 1,325.2% during the 2nd quarter. Federated Hermes Inc. now owns 23,572 shares of the financial services provider’s stock valued at $6,497,000 after acquiring an additional 21,918 shares during the last quarter. Nebula Research & Development LLC purchased a new position in CME Group in the second quarter worth $992,000. Finally, The Manufacturers Life Insurance Company boosted its stake in CME Group by 2.6% in the second quarter. The Manufacturers Life Insurance Company now owns 287,876 shares of the financial services provider’s stock worth $79,344,000 after buying an additional 7,397 shares in the last quarter. Institutional investors and hedge funds own 87.75% of the company’s stock.

About CME Group

CME Group Inc operates global derivatives marketplaces that provide trading, clearing and settlement services for a broad range of financial and commodity products. Its exchange platforms enable participants to manage risk, discover prices and gain exposure to asset classes including interest rates, equity indexes, foreign exchange, energy, metals, agricultural commodities and digital assets.

The company’s principal marketplaces include CME, CBOT, NYMEX and COMEX. Products are offered through futures and options contracts, with electronic trading available through CME Globex as well as exchange-based and privately negotiated transactions.